Results for imatinibom translation from Croatian to English

nemojte dojiti tijekom liječenja imatinibom teva.
do not breast-feed during the treatment with imatinib teva.

blastična faza s prethodnim liječenjem najmanje imatinibom
blast phase with prior treatment of at least imatinib

ponovno uvesti liječenje imatinibom u dozi od 600 mg.
resume treatment with imatinib at 600 mg.

tablica 3 režim kemoterapije korišten u kombinaciji s imatinibom
table 3 chemotherapy regimen used in combination with imatinib

tada se liječenje imatinibom može nastaviti uz sniženu dnevnu dozu.
treatment with imatinib may then be continued at a reduced daily dose.

ukoliko je potrebno, može se razmotriti prekid liječenja imatinibom.
when needed, discontinuation of imatinib treatment may be considered.

zabilježeni su izolirani spontani i literaturni slučajevi predoziranja imatinibom.
isolated cases of imatinib overdose have been reported spontaneously and in the literature.

nisu poznati dugoročni učinci produljene terapije imatinibom na rast djece.
the long-term effects of prolonged treatment with imatinib on growth in children are unknown.

bolesnici s gist-om su već isprobali liječenje imatinibom i sunitinibom.
patients with gist will have tried treatment with imatinib and sunitinib.

dugoročno liječenje imatinibom može biti povezano sa značajnim smanjenjem funkcije bubrega.
long-term treatment with imatinib may be associated with a clinically significant decline in renal function.

koristi se nakon neuspješnog liječenja imatinibom (drugog antineoplastičnog lijeka);
it is used after treatment with imatinib (another cancer medicine) has failed;

dugotrajno liječenje imatinibom može biti povezano s klinički značajnim padom funkcije bubrega.
long-term treatment with imatinib may be associated with a clinically significant decline in renal function.

21 bolesnik je liječen imatinibom 400 mg na dan, dok su preostala 3 bolesnika primala niže doze.
21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses.

21 bolesnik je liječen imatinibom od 400 mg na dan, dok su preostala 3 bolesnika primala niže doze.
21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses.

liječenje imatinibom izazvalo je brzi odgovor pedijatrijskih bolesnika s novodijagnosticiranim kml-om sa chr-om od
imatinib treatment induces a rapid response in newly diagnosed paediatric cml patients with a chr of 78% after

ako se tijekom primjene imatinibom razvije teška nehematološka nuspojava, liječenje se mora prekinuti sve do oporavka od nuspojava.
if a severe non-haematological adverse reaction develops with imatinib use, treatment must be withheld until the event has resolved.

ovo je kliničko ispitivanje uključivalo 7 bolesnika s mds/mpb-om koji su liječeni imatinibom 400 mg na dan.
this study included 7 patients with mds/mpd who were treated with imatinib 400 mg daily.

bolesnici su liječeni s imatinibom od 340 mg/m2/dan, bez prekida u odsutnosti toksičnosti vezane uz dozu.
patients were treated with imatinib 340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity.

liječenje imatinibom izazvalo je brzi odgovor u novodijagnosticiranih pedijatrijskih kml bolesnika sa pho- om od 78% nakon 8 tjedana terapije.
imatinib treatment induces a rapid response in newly diagnosed paediatric cml patients with a chr of 78% after 8 weeks of therapy.

randomizirano, multicentrično, nekomparativno ispitivanje otvorenog tipa provelo se u bolesnika u kojih početno liječenje imatinibom u dozi od 400 ili 600 mg nije bilo uspješno.
an open-label, randomised, non-comparative multicentre study was conducted in patients who failed initial treatment with 400 or 600 mg imatinib.